Look behind the lecture: who and what are we missing in real-world data?

22 Apr 2022

Written by MICHELLE TARVER (FDA)

Interviews ISPOR Methodology Real-world evidence Stakeholder engagement

Following the session at ISPOR—The Professional Society for Health Economics and Outcomes Research's (NJ, USA) Virtual ISPOR Europe 2021 (November 30–December 3), Michelle Tarver of the FDA (MD, USA) explores how much progress has been made in including social determinants of health (SDOH) in real-world data (RWD). Please could you introduce yourself, your organization(s) and provide a brief summary of your career to date? I am Michelle Tarver, the deputy director of the Office of Strategic Partnerships and Technology Innovation at the Center for Devices and Radiological Health (CDRH) within the FDA. Our office provides leadership and oversight for all...